Current research in the field of FTD is focused on understanding the genetic and molecular mechanisms underlying the condition. Advances in genetic sequencing technologies have led to the identification of new genetic mutations associated with congenital myopathies that cause FTD. Additionally, research is exploring novel therapeutic approaches, including gene therapy and targeted drug treatments, to address the root causes of fiber type disproportion and improve muscle function.
